Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Authors:
Open Access
- 1 January 2023
- journal article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 30 (1) , 129-133
Abstract
No abstract availableKeywords
Funding Information
- Soonchunhyang University
- National Research Foundation of Korea (2021R1I1A3059993, RS-2023-00251607)
This publication has 23 references indexed in Scilit:
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trialThe Lancet Diabetes & Endocrinology, 2022
- Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trialsClinics and Research in Hepatology and Gastroenterology, 2022
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHNew England Journal of Medicine, 2021
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trialNature Medicine, 2021
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2021
- Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsJournal of Hepatology, 2020
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionGastroenterology, 2020
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialThe Lancet, 2019
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2019
- Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver diseaseDiabetes, Obesity and Metabolism, 2018